Usher 1F Collaborative Inc
Usher 1F Collaborative Inc
Usher 1F Collaborative Inc
Programs
Usher Syndrome Research Funding
To fund medical research to find an effective treatment to save or restore the vision of those affected with Usher Syndrome Type 1F.GeographiesNot indicatedDatesJan 1, 2022 – Dec 31, 2022Source990No causes providedNo populations provided–$735.8KProgram 1 [2025]
2025 Grants to Research Labs: Harvard Medical School, David Corey Lab: $320,000 Development of gene therapies for Usher 1F University of Oregon Institute of Neuroscience, Monte Westerfield Lab: $80,000 Testing existing drugs for repurposing for Usher 1F 2025 Grant for year 4 of RUSH1F, 4-year natural history study in partnership with Foundation Fighting Blindness: $200,000. 2026 is year 4 of 4. This study will provide critical data for a future clinical trial. $5000 awarded to Usher Syndroom, Netherlands, for support/sponsorship of international Usher syndrome scientific research conference Total payment to Unravel Biosciences to identify drugs for repurposing for Usher 1F: $45,610 with an additional $45,610 due early 2026 at conclusion of study. Total grants awarded in 2025: $350,610 Key Research advances realized in 2025: Harvard conducting further preclinical testing of mini-gene Harvard team published the following paper in peer-reviewed journal: Mini-Pcdh15b Gene Therapy Rescues Visual Deficits in a Zebrafish Model of Usher Syndrome Type 1F https://www.biorxiv.org/content/10.1101/2025.11.05.686814v1 2 more papers in progress from Harvard lab for publication in 2026 Corey lab is now testing gene therapy from The Salk Institute, Samuel Pfaff lab, and early results are exciting. Hired a consultant to take our mini-gene through the next steps to apply for a clinical trial. Agreement in progress. Will include with 2026 audit since its not yet signed.GeographiesNot indicatedDatesJan 1, 2025 – Dec 31, 2025Source990No causes providedNo populations provided–$712.8K
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)